Achaogen’s Zemdri granted NTAP status by the CMS

Achaogen announced that the Centers for Medicare & Medicaid Services – CMS – has granted a new technology add-on payment, or NTAP, for Zemdri when administered in the hospital inpatient setting. The NTAP program will provide hospitals with a payment, in addition to the standard-of-care Diagnostic Related Group reimbursement, of up to 50% of the cost of Zemdr ifor a period of two to three years, effective in the 2019 fiscal year starting on October 1, 2018. CMS has assigned a maximum payment of $2,722.50 for a patient treated with ZEMDRI.

https://bit.ly/2ADyKTy